Kymera Therapeutics, Inc. (NASDAQ:KYMR) Insider Ellen Chiniara Sells 2,241 Shares

Kymera Therapeutics, Inc. (NASDAQ:KYMR) insider Ellen Chiniara sold 2,241 shares of the stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $30.45, for a total value of $68,238.45. Following the sale, the insider now directly owns 80,085 shares in the company, valued at $2,438,588.25. This trade represents a 2.72 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website.

Ellen Chiniara also recently made the following trade(s):

• On Monday, January 6th, Ellen Chiniara sold 3,129 shares of Kymera Therapeutics stock. The stock was sold at an average price of $41.75, for a total value of $130,635.75.

Kymera Therapeutics Stock Performance

Kymera Therapeutics stock opened at $30.17 on Tuesday. The business’s 50-day simple moving average is $38.81 and its two-hundred day simple moving average is $43.66. The company has a market cap of $1.95 billion, a PE ratio of -12.89 and a beta of 2.18. Kymera Therapeutics, Inc. has a fifty-two week low of $29.16 and a fifty-two week high of $53.27.

Kymera Therapeutics (NASDAQ:KYMR) last issued its quarterly earnings data on Thursday, February 27th. The company reported ($0.88) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.76) by ($0.12). The company had revenue of $7.39 million during the quarter, compared to analyst estimates of $14.81 million. Kymera Therapeutics had a negative net margin of 191.26% and a negative return on equity of 24.96%. As a group, analysts predict that Kymera Therapeutics, Inc. will post -2.79 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several research analysts recently weighed in on the company. BMO Capital Markets assumed coverage on Kymera Therapeutics in a research note on Friday, December 6th. They set a “market perform” rating and a $55.00 target price on the stock. Leerink Partners restated an “outperform” rating and set a $60.00 target price on shares of Kymera Therapeutics in a research note on Friday, December 27th. Stephens restated an “overweight” rating and set a $60.00 target price on shares of Kymera Therapeutics in a research note on Tuesday, January 21st. Morgan Stanley boosted their target price on Kymera Therapeutics from $45.00 to $49.00 and gave the stock an “equal weight” rating in a research note on Wednesday, November 6th. Finally, UBS Group dropped their target price on Kymera Therapeutics from $80.00 to $74.00 and set a “buy” rating on the stock in a research note on Monday, November 4th. Three investment analysts have rated the stock with a hold rating, ten have issued a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $56.69.

Hedge Funds Weigh In On Kymera Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of KYMR. Wellington Management Group LLP lifted its holdings in shares of Kymera Therapeutics by 14.9% in the 4th quarter. Wellington Management Group LLP now owns 5,307,326 shares of the company’s stock valued at $213,514,000 after buying an additional 688,967 shares during the period. Avoro Capital Advisors LLC lifted its holdings in shares of Kymera Therapeutics by 14.4% in the 4th quarter. Avoro Capital Advisors LLC now owns 5,150,000 shares of the company’s stock valued at $207,184,000 after buying an additional 650,000 shares during the period. Deerfield Management Company L.P. Series C acquired a new position in shares of Kymera Therapeutics in the 4th quarter valued at about $23,856,000. Boxer Capital Management LLC acquired a new position in shares of Kymera Therapeutics in the 4th quarter valued at about $17,098,000. Finally, Jennison Associates LLC lifted its holdings in shares of Kymera Therapeutics by 85.8% in the 3rd quarter. Jennison Associates LLC now owns 797,681 shares of the company’s stock valued at $37,754,000 after buying an additional 368,394 shares during the period.

About Kymera Therapeutics

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.